ImmuCell Corporation ICCC

ImmuCell Corp (ICCC) reports 11.5% sales growth and a 19% U.S. market share, while investing $8 million to triple manufacturing capacity.

Moby summary of ImmuCell Corporation's Q2 2026 earnings call

PORTLAND, Maine, Aug. 13, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops, manufactures and markets products to improve calf health and productivity, today announced its unaudited financial results for the quarter ended June 30, 2026. Management’s Discussion: “Today we are reporting net income of $1.8 million for the second quarter of 2026,” commented Timothy C. Fiori, Chief Financial Officer of ImmuCell

Conference Call Scheduled for Friday, August 14, 2026 at 9:00 AM ETPORTLAND, Maine, Aug. 06, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops, manufactures and markets products to improve calf health and productivity, expects to report unaudited financial results for the quarter ended June 30, 2026 after the market closes on Thursday, August 13, 2026. The Company is planning to host a conference call and

PORTLAND, Maine, July 09, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health biologics company that develops, manufactures and markets products to improve calf health and productivity, today announced preliminary, unaudited sales results for the second quarter of 2026. “Total sales for the three months ended June 30, 2026 were $7.2 million, an 11.5% increase compared to the three months ended June 30, 2025, driven by a 27.7% increase in d

ImmuCell Corp (ICCC) achieves its first-ever $10 million revenue quarter, driven by strong domestic sales and strategic product expansions.

Moby summary of ImmuCell Corporation's Q1 2026 earnings call